Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.

Abstract: A data processing method that is suitable for use in a time-of-flight sensor includes the following steps. A processing unit reads a first stage of time-slot counting data corresponding to the time-of-flight sensor from a storage unit. The processing unit generates an overflow warning signal according to the first time-slot counting data and a first predetermined threshold. The processing unit reads a second stage of time-slot counting data, wherein the second time-slot counting data are greater than or equal to the first time-slot counting data, and the second time-slot counting data are generated by the time-of-flight sensor performing a sensing operation based on the first time-slot counting data. The processing unit subtracts a second predetermined threshold from the second time-slot counting data to generate a third stage of time-slot counting data or maintains the second time-slot counting data according to the overflow warning signal.

Abstract: A control device suitable for use in a time-of-flight sensor is provided. The control device includes a storage unit and a control unit. The storage unit records the count data corresponding to the photon trigger number of the time-of-flight sensor. The control unit is coupled to the storage unit. The control unit reads the count data, obtains the modulation ratio corresponding to the counting range according to the count data, generates a control signal corresponding to the modulation ratio of each counting range, and transmits the control signal to the time-of-flight sensor, so as to control the operation of the time-of-flight sensor.

Abstract: At least a glove part covers a glove core of a glove structure to simulate dermis and epidermis of skin. The glove part is formed with a lamination region which caves downwards from a top surface of the glove part and has a long strip shape along an extending direction, and the lamination region acts as the sulcus cutis of the palm prints of the epidermis. The lamination region has an adhesion region, a bottom portion, protruding portions and sinking sections. A portion of the top surface not formed with the lamination region has at least a non-lamination region. The bottom portion between the protruding portion and the non-lamination region acts as the sulcus cutis. The protruding portions of the bottom portion act as the crista cutis of the palm prints. The sinking section between the adjacent protruding portions acts as the sinking region of the palm prints.

Abstract: Methods and apparatus to perform mask-based depth enhancement for multi-view systems are disclosed herein. An example apparatus to adjust an input depth image of an image frame including the input depth image and an input color image includes at least one memory, instructions in the apparatus, and processor circuitry to execute the instructions to identify a color patch and a depth patch for an image pixel in a border area of the image frame, output an adjusted depth map based on at least one of (i) a mismatch between values of the color patch and a center pixel color of the color patch or (ii) a mismatch between values of the depth patch and a center pixel depth of the depth patch, output an adjusted mask map associated with the input depth image based on a position of at least one camera used to capture the image, and perform iterative depth data gap filling based on the adjusted depth map and the adjusted mask map to obtain an adjusted depth image corresponding to the input depth image.

Abstract: A composition of drug targets and the method of using thereof. The composition comprises a vector and a drug using FKBP10 and PCOLCE genes and/or the encoded proteins thereof as drug targets.

Abstract: The present disclosure provides an LED display module and an LED display device. The LED display module includes a display module body and a lock. The lock includes: a lock seat arranged on a rear side of the display module body; a lock cylinder rotatably arranged in the lock seat; a locking member; an interference member rotatably sleeved on the lock cylinder and spaced apart from the locking member along the axial direction of the lock cylinder, the interference member having an interference position where the interference member locates on a front side of a connecting beam for lifting up the display module body and an avoidance position where the interference member avoids the connecting beam; and an elastic linkage member arranged between the locking member and the interference member. When the locking member is in an unlocking position, the interference member is driven to an interference position by the elastic linkage member.

Abstract: The present invention relates to a process for the production of metal alloy nanoparticles which catalyse the oxygen reduction reaction (ORR) for use in proton exchange membrane fuel cells (PEMFC) or electrolyser cells. In particular, the present invention relates to a process for producing alloy nanoparticles from platinum group metals and other metals under reductive conditions. In particular the present invention relates to a process for producing alloy nanoparticles comprising the steps of mixing a salt of at least one metal, a material comprising a platinum group metal, a nitrogen-rich compound, and optionally a support material, to provide a precursor mixture, and heating said precursor mixture to a temperature of at least 400° C., in the presence of a gas comprising hydrogen (H2), to provide said alloy nanoparticles.

Abstract: The current invention provides a method of activating fibroblast and myofibroblast apoptosis in a tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGFB1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine polymer. The invention also provides additional methods for using this composition.

Abstract: A composition of drug targets and the use the method of using thereof. The composition comprises a vector and a drug using FKBP10 and PCOLCE genes and/or the encoded proteins thereof as drug targets.

Abstract: The invention relates to a method for welding a first workpiece (11) to a second workpiece (12) by means of a laser. It is an object of the invention to provide a reliable, repeatable and reproducible approach for laser welding of two workpieces one of which consists of a semiconductor material.

Abstract: A method for assessing a condition of an organ or tissue of a target object is provided. The method may include: obtaining a target image of the target object; segmenting a target region from the target image, the target region of the target image corresponding to a sub-region of the organ or tissue; determining a morphological characteristic value of the target region in the target image; obtaining a reference standard associated with a sample organ or tissue of a plurality of sample objects, the sample organ or tissue being of a same type as the organ or tissue of the target object; and assessing the condition of the organ or tissue of the target object by comparing the morphological characteristic value of the target region in the target image with the reference standard.

Abstract: Use of glycerol in preparing an adipose tissue cryopreservation protective agent and the adipose tissue cryopreservation protective agent. Based on the total volume of the adipose tissue cryopreservation protective agent, the adipose tissue cryopreservation protective agent includes: glycerol with a volume fraction of 60-80%; 0.090-0.200 g/ml trehalose; and a PBS buffer serving as the solvent. The adipose tissue cryopreservation protective agent is free of DMSO and other protective agents having biological toxicity, poses no toxicity to cells and tissues, and causes no safety problem during clinical use even in a case of incomplete elution. The adipose tissue cryopreservation protective agent is free of xenoantigen and has low cost. With glycerol and trehalose being clinically approved medicinal ingredients and inexpensive products, the agent of the present disclosure contains no costly products such as human albumin, thus providing increased possibility for clinical use and promotion.